BIOCON - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.3
| Stock Code | BIOCON | Market Cap | 61,926 Cr. | Current Price | 382 ₹ | High / Low | 425 ₹ |
| Stock P/E | 318 | Book Value | 120 ₹ | Dividend Yield | 0.13 % | ROCE | 2.09 % |
| ROE | 0.40 % | Face Value | 5.00 ₹ | DMA 50 | 383 ₹ | DMA 200 | 372 ₹ |
| Chg in FII Hold | 0.53 % | Chg in DII Hold | 2.07 % | PAT Qtr | 111 Cr. | PAT Prev Qtr | 70.9 Cr. |
| RSI | 48.7 | MACD | 0.96 | Volume | 23,16,385 | Avg Vol 1Wk | 30,38,683 |
| Low price | 295 ₹ | High price | 425 ₹ | PEG Ratio | -17.1 | Debt to equity | 0.16 |
| 52w Index | 67.1 % | Qtr Profit Var | 3,183 % | EPS | 0.07 ₹ | Industry PE | 27.6 |
📊 Chart & Trend Analysis: BIOCON is trading at ₹382, hovering near its 50 DMA (₹383) and slightly above its 200 DMA (₹372), indicating indecision. RSI at 48.7 shows neutral momentum, while MACD at 0.96 reflects mild positive bias. Bollinger Bands suggest price is mid-range, pointing to consolidation.
📈 Momentum Signals: Volume (23.1L) is lower than 1-week average (30.3L), showing reduced participation. Neutral RSI and weak MACD together highlight sideways momentum with limited strength.
💹 Entry Zone: Strong support lies around ₹365–₹375 (near 200 DMA). Accumulation near this zone offers risk-managed entry.
💰 Exit Zone: Resistance levels are ₹400–₹425. A breakout above ₹425 would confirm bullish reversal.
🔎 Trend Status: The stock is consolidating with neutral bias. Sustained move above ₹400 backed by volume is required to regain bullish momentum.
Positive
- Quarterly PAT growth (₹111 Cr vs ₹70.9 Cr) shows improving profitability.
- DII holding increased (+2.07%), reflecting strong domestic institutional support.
- 52-week index gain of 67.1% highlights strong sectoral performance.
Limitation
- Extremely high P/E (318) compared to industry average (27.6), making valuation expensive.
- Low ROCE (2.09%) and ROE (0.40%) indicate weak efficiency.
- EPS at ₹0.07 remains very low relative to valuation.
Company Negative News
- High leverage risk with weak profitability metrics.
- PEG ratio (-17.1) highlights poor growth-to-valuation balance.
Company Positive News
- Quarterly profit variation (+3,183% YoY) reflects strong operational turnaround.
- Both FII (+0.53%) and DII (+2.07%) holdings increased, showing balanced institutional confidence.
Industry
- Biopharma sector benefits from rising global healthcare demand and innovation.
- Industry P/E at 27.6 indicates BIOCON trades at a steep premium (P/E 318).
Conclusion
⚖️ BIOCON is fundamentally improving with strong quarterly profit growth, but valuations remain stretched and efficiency ratios are weak. Technically, the stock is consolidating near support zones. Entry near ₹365–₹375 offers favorable risk-reward, while breakout above ₹425 could trigger fresh upside. Long-term investors should accumulate cautiously, while traders should wait for volume-backed breakout confirmation.
Would you like me to extend this into a peer benchmarking overlay with Sun Pharma, Dr. Reddy’s, and Cipla so you can compare BIOCON’s momentum against the broader pharma sector rotation?